MYDECINE

Mydecine Innovations Group Featured in Forbes for the First-Of-Its-Kind Clinicals Using Psilocybin Therapy For PTSD

← Back to all news
August 13, 2020

DENVER, Colorado, USA, August 13, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company"), is pleased to announce that NeuroPharm Inc., a company focused on developing unique mental health therapies and approaches for veteran wellness, was recently covered in Forbes for its ground-breaking psilocybin clinical trials for treatment of posttraumatic stress disorder (PTSD).

Conducted in collaboration with Leiden University Medical Center of The Netherlands (LUMC) and the ARQ National Psychotrauma Centre, the first phase of the trial will include three doses of psilocybin spread out over three weeks and is believed to be the first clinical trial of its kind.

Speaking with award-winning journalist Javier Hasse, NeuroPharm Scientific Advisor Dr. Rakesh Jetly, OMM, CD, MD,FRCPC said that evidence suggests that military veterans are particularly difficult to treat using conventional therapies, which increases the need for novel therapies like psilocybin.

“These preliminary trials have been so impressive that they have led to the FDA to designate MDMA and psilocybin ‘breakthrough therapies’ for PTSD and treatment-resistant depression, respectively,” commented Dr. Jetly.

The clinical trials are expected to first begin in LUMC later this year, under the supervision of Prof. Eric Vermetten, and then later advanced throughout Europe, North America and the Caribbean.

Click here to read the full Forbes article.

Mydecine has entered into a definitive acquisition agreement with NeuroPharm Inc., for the acquisition of all of its outstanding shares and will be proceeding with closing in the coming days.